Read by QxMD icon Read

Srs/sbrt reviews

shared collection
17 papers 25 to 100 followers
Lisa Deloch, Anja Derer, Josefin Hartmann, Benjamin Frey, Rainer Fietkau, Udo S Gaipl
Even though there is extensive research carried out in radiation oncology, most of the clinical studies focus on the effects of radiation on the local tumor tissue and deal with normal tissue side effects. The influence of dose fractionation and timing particularly with regard to immune activation is not satisfactorily investigated so far. This review, therefore, summarizes current knowledge on concepts of modern radiotherapy (RT) and evaluates the potential of RT for immune activation. Focus is set on radiation-induced forms of tumor cell death and consecutively the immunogenicity of the tumor cells...
2016: Frontiers in Oncology
Genevieve Maquilan, Robert Timmerman
Stereotactic body radiation therapy (SBRT), also known as stereotactic ablative radiotherapy, is a technique of external beam radiation that delivers precisely targeted, ablative doses to extracranial sites. It has become an integral component of the management of early-stage non-small cell lung cancer (NSCLC). In this review, we discuss the technology and techniques used in treatment planning and delivery, the efficacy and toxicity of SBRT for medically inoperable early-stage NSCLC, and the preliminary investigations into the role of SBRT for operable early-stage NSCLC...
July 2016: Cancer Journal
Rohann J M Correa, Joseph K Salama, Michael T Milano, David A Palma
Oligometastasis refers to a state of limited metastatic disease burden, in which surgical or ablative treatment to all known visible metastases holds promise to extend survival or even effect cure. Stereotactic body radiotherapy is a form of radiation treatment capable of delivering a high biologically effective dose of radiation in a highly conformal manner, with a favorable toxicity profile. Enthusiasm for oligometastasis ablation, however, should be counterbalanced against the limited supporting evidence...
July 2016: Cancer Journal
Meghan Campo, Hani Al-Halabi, Melin Khandekar, Alice T Shaw, Lecia V Sequist, Henning Willers
UNLABELLED: : Genotype-based selection of patients for targeted therapies has had a substantial impact on the treatment of non-small cell lung cancers (NSCLCs). Tyrosine kinase inhibitors (TKIs) directed at cancers driven by oncogenes, such as epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements, often achieve dramatic responses and result in prolonged survival compared with chemotherapy. However, TKI resistance invariably develops. Disease progression can be limited to only one or a few sites and might not be symptomatic, raising the important question of whether this type of oligoprogression warrants a change in systemic therapy or consideration of local treatment...
August 2016: Oncologist
Ashray Gunjur, Cuong Duong, David Ball, Shankar Siva
BACKGROUND: We systematically reviewed the literature on the use of surgery, stereotactic ablative body radiotherapy (SABR) and percutaneous catheter ablation (PCA) techniques for the treatment of adrenal metastases to develop evidence-based recommendations. METHODS: A systematic review of the MEDLINE database was performed using structured search terms following PRISMA guidelines. Eligible publications were those published from 1990 to 2012, written in English, had at least five patients treated for adrenal metastasis and reported on patient clinical outcomes (local control, survival and treatment related complications/toxicity)...
August 2014: Cancer Treatment Reviews
Patrick Cheung, Isabelle Thibault, Georg A Bjarnason
PURPOSE OF REVIEW: To discuss the emerging roles of stereotactic ablative radiotherapy (SABR) in patients with metastatic renal cell carcinoma (RCC). RECENT FINDINGS: RCC tumours are not as radio-resistant as previously thought, as local control rates of tumours treated with SABR are high. Therefore, SABR is an attractive treatment option for RCC tumours in which effective long-term palliation of symptoms or local control is desired. Like surgical resection of metastatic tumours, SABR can also be used as a method of eradicating oligometastases to potentially 'cure' or offer prolonged disease-free survival in patients with low-volume metastatic disease...
September 2014: Current Opinion in Supportive and Palliative Care
Joseph K Salama, Michael T Milano
Advances in radiotherapy planning and delivery have been used to treat patients with limited metastatic disease. With these techniques, high rates of treated metastasis control and low toxicity have been reported. Some patients have long disease-free intervals after radiotherapy similar to those seen after surgical resection. Ongoing studies will determine the benefit of these irradiation techniques to treat limited metastases, identify appropriate candidates, and assist in integrating these treatments into management strategies for specific diseases...
September 10, 2014: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Fang Huang, Gang Wu, Kunyu Yang
The standard treatment choice for cancer metastasis has been systemic management, including cytotoxic chemotherapy, hormonal manipulation, and targeted therapy. Emerging evidence has shown an oligometastatic state, an intermediate state between limited primary cancer and polymetastatic cancer, in which local therapy for metastatic lesions results in satisfactory survival comparable to non-metastatic disease. We provide a comprehensive introduction of evidence from experimental and clinical studies in favor of the oligometastatic phenotype, we review the efficacy and safety of surgery and stereotactic body radiotherapy in the treatment of oligometastases, and finally, we discuss the way to differentiate the oligometastatic state from polymetastasis...
2014: Radiation Oncology
Stephen L Lewis, Sandro Porceddu, Naoki Nakamura, David A Palma, Simon S Lo, Peter Hoskin, Drew Moghanaki, Steven J Chmura, Joseph K Salama
PURPOSE: Stereotactic body radiotherapy (SBRT) is often used to treat patients with oligometastases (OM). Yet, patterns of SBRT practice for OM are unknown. Therefore, we surveyed radiation oncologists internationally, to understand how and when SBRT is used for OM. METHODS: A 25-question survey was distributed to radiation oncologists. Respondents using SBRT for OM were asked how long they have been treating OM, number of patients treated, organs treated, primary reason for use, doses used, and future intentions...
August 2017: American Journal of Clinical Oncology
I S Bhattacharya, D K Woolf, R J Hughes, N Shah, M Harrison, P J Ostler, P J Hoskin
OBJECTIVE: A review of stereotactic body radiotherapy (SBRT) for oligometastases defined as three or fewer sites of isolated metastatic disease. The aim was to identify local control, overall survival (OS) and progression-free survival (PFS) of patients receiving SBRT for oligometastatic (OM) disease. METHODS: Data were analysed for SBRT delivered between 01 September 2010 and 31 March 2014. End points included local control, PFS, OS and toxicity. RESULTS: 76 patients received SBRT...
April 2015: British Journal of Radiology
F Macbeth, T Treasure
No abstract text is available yet for this article.
August 2016: Clinical Oncology: a Journal of the Royal College of Radiologists
A Perrakis, T A Juratli, W Hohenberger, R S Croner, G Schackert
The surgical resection of metastases is nowadays feasible in selected patients with multifocal metastatic disease due to the implementation of interdisciplinary multimodal therapeutic options. Anatomical limitations do not seem to represent obstacles which cannot be overcome because of the development of new surgical techniques. The cornerstone of the selection of patients is the correct staging diagnosis achieved through modern diagnostic tools; however, surgery alone does not always offer acceptable survival and recurrence-free rates...
March 2016: Der Chirurg; Zeitschrift Für Alle Gebiete der Operativen Medizen
Kamran A Ahmed, Javier F Torres-Roca
BACKGROUND: The treatment of oligometastatic disease has become common as imaging techniques have advanced and the management of systemic disease has improved. Use of highly targeted, hypofractionated regimens of stereotactic body radiotherapy (SBRT) is now a primary management option for patients with oligometastatic disease. METHODS: The properties of SBRT are summarized and the results of retrospective and prospective studies of SBRT use in the management of oligometastases are reviewed...
January 2016: Cancer Control: Journal of the Moffitt Cancer Center
Myungsoo Kim, Seok Hyun Son, Yong Kyun Won, Chul Seung Kay
Liver metastasis in solid tumors, including colorectal cancer, is the most frequent and lethal complication. The development of systemic therapy has led to prolonged survival. However, in selected patients with a finite number of discrete lesions in liver, defined as oligometastatic state, additional local therapies such as surgical resection, radiofrequency ablation, cryotherapy, and radiotherapy can lead to permanent local disease control and improve survival. Among these, an advance in radiation therapy made it possible to deliver high dose radiation to the tumor more accurately, without impairing the liver function...
2014: BioMed Research International
Atsuya Takeda, Naoko Sanuki, Etsuo Kunieda
Systemic chemotherapy has enabled prolongation of survival in patients with stage IV colorectal cancer. This has subsequently increased the relative significance of local therapy for patients with oligometastases because they can be cured by removal of oligometastatic lesions. One of the most frequently reported tumor histologies for oligometastases is colorectal cancer. Resection is the standard therapy in most settings of oligometastases. Recently, studies have shown that stereotactic body radiotherapy (SBRT) may become a treatment option that provides high local control with minimal morbidity...
April 21, 2014: World Journal of Gastroenterology: WJG
Young Seok Seo, Mi-Sook Kim, Hyung-Jun Yoo, Won-Il Jang
Recurrence of colorectal cancer (CRC) often presents as solitary metastases, oligometastases or oligo-recurrence. Surgical resection became the preferred treatment for patients with CRC lung and hepatic metastases. However, surgical treatment for oligo-recurrence within nodal area is not a widely accepted treatment due to due to their relative rarity and high postoperative morbidity. Stereotactic body radiotherapy (SBRT) is one of the emerging radiation treatment techniques in which a high radiation dose can be delivered to the tumor...
February 28, 2014: World Journal of Gastroenterology: WJG
Michael T Milano, Alan W Katz, Michael C Schell, Abraham Philip, Paul Okunieff
PURPOSE: To characterize oligometastases in patients enrolled on two prospective pilot studies, treating oligometastases with hypofractionated stereotactic body radiotherapy and stereotactic radiosurgery to cranial lesions. METHODS AND MATERIALS: We describe the characteristics and local control (LC) of 293 lesions in 121 patients with five or fewer metastases treated with stereotactic body radiation and/or cranial stereotactic radiosurgery. For each lesion, the primary cancer site, tumor histology, site of metastasis, gross tumor volume, and prescribed dose were ascertained...
December 1, 2008: International Journal of Radiation Oncology, Biology, Physics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"